ArticleAnnals of surgical oncology2026
Multimodal Management of Retroperitoneal Lymph Node Metastases in Colorectal Cancer: A Single-Center Retrospective Analysis.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRetroperitoneal lymph node metastases (RLNMs) of colorectal cancer (CRC) have a low incidence, and the optimal treatment strategy remains unclear due to limited evidence. This study aimed to analyze morbidity and long-term oncologic outcomes associated with different multimodal approaches including systemic chemotherapy, surgery with or without preoperative radiotherapy.
methodsThis retrospective, single-center study included consecutive patients treated from 2000 to 2023 for sub-renal RLNM from CRC. After induction chemotherapy, the patients were divided into two groups: those receiving radio(chemo)therapy (RCT) followed by surgery (RCT-surgery group; n = 30) and those undergoing upfront surgery (surgery-alone group; n = 24). The study analyzed treatment methods, perioperative data, morbidity, mortality, overall survival (OS), and recurrence-free survival (RFS).
resultsThe study included 54 patients (32 males, 22 females, age 51 years). Presentation of RLNM was synchronous in 48.1% (n = 25) of the patients, and 25.9% (n = 14) of the patients had previously treated extra-nodal metastases. Standardized retroperitoneal nodal dissection (RND) was performed for 40 (90.7%) patients. Operative time, blood loss, severe postoperative morbidity, and hospital length of stay were similar between the RCT-surgery and surgery-alone groups. Preoperative RCT was associated with a higher rate of complete response (18.2% vs 0%; p = 0.018). The median RFS was 13.1 months for the RCT-surgery group and 8.6 months for the surgery-alone group (p = 0.153). The median OS was 73.9 months for the surgery-alone group and not reached in the RCT-surgery group (p = 0.909).
conclusionA multimodal curative strategy combining nodal dissection after systemic chemotherapy with or without preoperative RCT for RLNM from CRC is feasible, demonstrating low morbidity and promising oncologic outcomes in advanced metastatic disease.
Indexed as
Identifiers
41087778What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.